Heart Failure Drugs: β-Blockers

β-blockers counteract sympathetic overstimulation by reducing heart rate, contractility, and cardiac workload. They inhibit renin production and catecholamine-induced mitogenicity, preventing cardiac remodeling. These drugs improve left ventricular ejection fraction, reduce sudden cardiac death risk, and enhance myocardial perfusion in clinically stable patients with symptomatic heart failure or left ventricular dysfunction.

When blood pressure decreases in heart failure, baroreceptors trigger sympathetic mechanisms that increase heart rate and contractility. Released catecholamines cause vasoconstriction, enhancing venous return and preload to improve cardiac output. However, these compensatory actions increase cardiac workload and worsen heart failure symptoms over time, necessitating β-blocker intervention.

Carvedilol is a nonselective third-generation β-blocker with α1-receptor antagonist properties and vasodilatory effects. Nebivolol is β1-selective with additional vasodilatory actions. Both agents benefit heart failure patients, but carvedilol's nonselective nature may cause adverse effects like bradycardia, peripheral vasoconstriction, and bronchoconstriction, requiring careful dose titration.

β-blockers must be initiated at low doses and gradually increased based on patient tolerance and vital signs. Nonselective agents can induce adverse effects including bradycardia, peripheral vasoconstriction, and bronchoconstriction. Careful titration minimizes these risks while allowing the body to adapt, ensuring optimal therapeutic benefits in heart failure management.

β-blockers shift the concentration-response curve of catecholamines to the right, reversing the adverse gene program caused by chronic sympathetic stimulation. By blocking sympathetic neurotransmitters like noradrenaline and adrenaline, they reduce heart rate, contractile force, and cardiac muscle relaxation, while also slowing atrial-ventricular conduction and raising arrhythmia thresholds.

Beyond cardiac effects, β-blockers inhibit renin release from the macula densa and suppress hepatic glucose production. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and vasoconstriction. These metabolic actions contribute to their overall therapeutic benefit in reducing cardiac workload and improving survival in chronic heart failure.

Several β-blockers have demonstrated clinical efficacy in heart failure trials, including metoprolol, bisoprolol, carvedilol, and nebivolol. These agents are recommended for clinically stable patients with symptomatic heart failure or left ventricular dysfunction after myocardial infarction. Proper dosing accounting for pharmacokinetic differences is essential for successful therapy.